Genmab A/S (NASDAQ:GMAB) Hits New 1-Year High - What's Next?

Key Points

• Genmab A/S's stock reached a new 52-week high of $33.65 during trading, with a closing price of $33.21.
• Analysts are optimistic, with ratings indicating a consensus of "Moderate Buy" and a target price averaging around $40.80 per share.
• In its latest quarterly earnings, Genmab reported $0.54 earnings per share, exceeding analysts' expectations significantly.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report)'s share price reached a new 52-week high during trading on Thursday . The stock traded as high as $33.65 and last traded at $33.21, with a volume of 736304 shares. The stock had previously closed at $32.72.

Analyst Ratings Changes

Several equities research analysts have commented on the company. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Genmab A/S in a report on Wednesday. Truist Financial boosted their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Guggenheim upgraded Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 price target for the company in a research note on Tuesday, September 23rd. Zacks Research upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, October 2nd. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Genmab A/S currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.80.

Genmab A/S Price Performance

The firm has a market cap of $21.13 billion, a PE ratio of 16.52, a PEG ratio of 1.85 and a beta of 0.98. The business has a 50-day simple moving average of $27.51 and a 200 day simple moving average of $23.13.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Hedge funds have recently made changes to their positions in the business. Foresight Group Ltd Liability Partnership bought a new position in shares of Genmab A/S in the first quarter worth about $954,000. Vident Advisory LLC bought a new position in Genmab A/S during the first quarter valued at approximately $242,000. GAMMA Investing LLC boosted its stake in Genmab A/S by 1,465.3% during the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company's stock valued at $656,000 after buying an additional 31,343 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in Genmab A/S during the second quarter valued at approximately $257,000. Finally, DAVENPORT & Co LLC boosted its stake in Genmab A/S by 6.8% during the second quarter. DAVENPORT & Co LLC now owns 33,826 shares of the company's stock valued at $699,000 after buying an additional 2,147 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.